Clinical Trials Logo

Sleep Apnea, Obstructive clinical trials

View clinical trials related to Sleep Apnea, Obstructive.

Filter by:

NCT ID: NCT04648618 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea and Diabetic Macular Edema Inflammatory Mediators

Start date: January 1, 2018
Phase:
Study type: Observational

Obstructive sleep apnea (OSA) is characterized by intermittent nocturnal hypoxemia, frequent arousals, fragmented sleep and daytime sleepiness. It has been shown to increase the risk of cardiac and vascular disease through multiple mechanisms including sympathetic hyperactivity, metabolic dysregulation, and activation of oxidative stress and inflammatory pathways. Diabetic retinopathy is a leading cause of blindness in the working age group, affecting 93 million people worldwide. Diabetic macular edema (DME) is a sight threatening complication and the most common cause of visual loss in patients with diabetes. OSA is frequently associated with diabetes with prevalence ranging from 23 to 86%. However, the relationship between OSA and DME is not well defined. The retina is especially susceptible to hypoxia, being one of the most metabolically active tissues. Many of the same inflammatory mediators have also been found to be elevated in patients with diabetic macular edema, including VEGF, VCAM-1 and IL-6. There has been no previous study examining the biochemical impact of OSA on patients with DME. We aim to explore this relationship by examining the differences in inflammatory markers expressed in patients with DME who have undergone an overnight sleep study, which is considered the gold standard diagnostic tool in OSA.

NCT ID: NCT04646902 Active, not recruiting - Clinical trials for Hypertension Secondary

Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea

KYNTOSA
Start date: March 25, 2021
Phase:
Study type: Observational

Obstructive Sleep Apnea (OSA) is an independent risk factor for hypertension (HTN) and the most common cause of resistant HTN. The mechanisms underlying OSA-associated HTN are not completely understood. This is crucial to find novel therapeutic targets of OSA-associated HTN. The Aryl Hydrocarbon Receptor (AHR) is a cytosolic transcription factor that has been linked with the pathogenesis of HTN. This study aims to evaluate the role of endogenous ligands of AHR such as kynurenine in discriminating patients with OSA-associated HTN. For that aim, a case-control study will be performed in patients with and without hypertension exposed and not exposed to OSA. Kynurenine and other metabolites will be quantified in urine and serum samples.

NCT ID: NCT04632147 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea Syndrome

The Effect of Pranayamic Techniques on Obstructive Sleep Apnea Syndrome

Start date: April 20, 2021
Phase: N/A
Study type: Interventional

Study was planned to investigate the effect of pranayama on dyspnea, daytime sleepiness, cognitive function, quality of life, activities of daily living, functional exercise capacity, physical activity level, sleep quality, fatigue, musculoskeletal pain, depression and anxiety in OSAS.

NCT ID: NCT04363333 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea & Covid-19 Outcomes

OSACOVID-19
Start date: April 27, 2020
Phase:
Study type: Observational

Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.

NCT ID: NCT04349397 Active, not recruiting - Pain, Postoperative Clinical Trials

Use of Analgesics and Pain Scores After Pediatric Adenotonsillectomy

Start date: August 1, 2019
Phase:
Study type: Observational

The purpose of the study is to quantify the use of pain medications given to children aged 3 - 12 years as well as their pain level through pain scores after they have undergone a tonsillectomy or adenotonsillectomy surgery at Doernbecher Children's Hospital (DCH). We would like to learn more about the pain medications given and the pain scores of children post-surgery for the first 5 days following discharge from the hospital.

NCT ID: NCT04322162 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Addressing Sleep Apnea Post-Stroke/TIA

ASAP
Start date: April 2, 2020
Phase: N/A
Study type: Interventional

Effectively identifying and treating risk factors for ischemic stroke and transient ischemic attack (TIA) is important to patients, their family members, and healthcare systems. While obstructive sleep apnea (OSA) is a known risk factor for stroke and TIA that is present in more than 70% of stroke/TIA survivors, testing for OSA is infrequently performed for patients and within healthcare systems. The Addressing Sleep Apnea Post-Stroke/TIA (ASAP) study intends to improve rates of guideline-recommended OSA testing and treatment through local quality improvement initiatives (QI) conducted within and across 6 VA Medical Centers. ASAP will also determine the impact of these local QI initiatives on rates of OSA diagnosis, OSA treatment, recurrent vascular events, and hospital readmissions.

NCT ID: NCT04305964 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Nasal Airway Stent (Nastent®) Study in OSA

Nastent
Start date: May 1, 2020
Phase: N/A
Study type: Interventional

This study intends to assess the effect of nasal airway stent (Nasten®) as a treatment modality in patients with sleep-disordered breathing (SDB) including snoring and/or obstructive sleep apnea (OSA). Nastent®, a distally perforated soft silicon nasal tube, is a mechanical splint against collapse of the upper airway at multiple levels. Nastent® might be able to prevent the vibrations caused by fluttering of various parts of the upper airway which leads to snoring. Furthermore, it also potentially secures a patent airway throughout the night securing airflow.

NCT ID: NCT04263363 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications

Start date: February 18, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to: 1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and implement a clinical best practice pathway designed to prevent postoperative respiratory complications in higher risk patients (such as those with OSA or preexisting respiratory disease) using education and clinical decision support in patients.

NCT ID: NCT04227093 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Acetazolamide Add-On Therapy to OSA Surgery

ACTOS
Start date: January 22, 2020
Phase: Phase 4
Study type: Interventional

Surgical procedures are routinely performed as an alternative to continuous positive airway pressure treatment in patients with obstructive sleep apnea (OSA). However, the response to surgery is often variable. Instability of the respiratory control during sleep (or high loop gain) has been associated with poor surgical results in previous research. Acetazolamide (AZM), a carbonic anhydrase inhibitor, has shown potential in reducing loop gain without affecting other physiological OSA traits. In this protocol the investigators will evaluate the clinical efficacy of AZM add-on therapy to surgical procedures in patients with OSA.

NCT ID: NCT04187612 Active, not recruiting - Obesity Clinical Trials

Association of Body Fluid Distribution With Obstructive Sleep Apnea in Pregnant Women With Body Mass Index ≥ 40 kg/m2

Start date: December 2, 2019
Phase:
Study type: Observational

Obstructive Sleep apnea (OSA) is a common and underdiagnosed condition in obese pregnant women with serious and life-threatening complications to the mother and baby. The investiators propose that a non-invasive method may be used to detect patients at risk of OSA, giving these women access to the necessary treatment to treat this condition. The method is a estimation of body water, which has been shown to be linked to OSA in the non-pregnant population. Body water is estimated by applying surface electrodes to a participant who is lying down by measuring bioimpedance through body tissues by applying a tiny current between the electrodes. The electrical stimulation is not felt by the participant and has no negative effects on mother or baby.